A federal appeals court has upheld a Boehringer Ingelheim
patent for its Parkinson’s disease drug Mirapex, overturning a lower court decision.
The U.S. Court of Appeals for the Federal Circuit ruled that the ’812 patent, which has delayed Mylan’s plans to market a generic version of
Mirapex (pramipexole dihydrochloride), is valid because it is covered by the safe harbor provision of Section 121 of the patent law. The patent expires
Oct. 8, according to the FDA Orange Book. Generic Line